Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation
Erik Bathoorn1, Jeroen JW Liesker1, Dirkje S Postma1, Gerard H Koëter1, Marco van der Toorn2, Sicco van der Heide2, H Alec Ross3, Antoon JM van Oosterhout2, Huib AM Kerstjens1
1Department of Pulmonology; 2Laboratory of Allergology and Pulmonary Diseases, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, the Netherlands; 3Department of Chemical Endocrinology, Radboud University Nijmegen Medical Centre, the Netherlands
Background: Inflammation increases during exacerbations of COPD, but only a few studies systematically assessed these changes. Better identification of these changes will increase our knowledge and potentially guide therapy, for instance by helping with quicker distinction of bacterially induced exacerbations from other causes.
Aim: To identify which inflammatory parameters increase during COPD exacerbations compared to stable disease, and to compare bacterial and non-bacterial exacerbations.
Methods: In 45 COPD patients (37 male/8 female, 21 current smokers, mean age 65, FEV1 52% predicted, pack years 38) sputum was collected during a stable phase and subsequently during an exacerbation.
Results: Sputum total cell counts (9.0 versus 7.9 × 106/mL), eosinophils (0.3 versus 0.2 × 106/mL), neutrophils (6.1 versus 5.8 × 106/mL), and lymphocytes (0.07 versus 0.02 × 106/mL) increased significantly during an exacerbation compared to stable disease. A bacterial infection was demonstrated by culture in 8 sputum samples obtained during an exacerbation. These exacerbations had significantly increased sputum total cell and neutrophil counts, leukotriene-B4, myeloperoxidase, interleukin-8 and interleukin-6, and tumor necrosis factor-α (TNF-α) levels, and were also associated with more systemic inflammation compared to exacerbations without a bacterial infection. Sputum TNF-α level during an exacerbation had the best test characteristics to predict a bacterial infection.
Conclusion: Sputum eosinophil, neutrophil, and lymphocyte counts increase during COPD exacerbations. The increase in systemic inflammation during exacerbations seems to be limited to exacerbations caused by bacterial infections of the lower airways. Sputum TNF-α is a candidate marker for predicting airway bacterial infection.
Keywords: chronic obstructive pulmonary disease, exacerbation, inflammation, sputum induction
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Other article by this author:
Erik Bathoorn, Huib Kerstjens, Dirkje Postma, Wim Timens, William MacNee
Published Date: 6 June 2008
Readers of this article also read:
A role of Yueju in fast-onset antidepressant action on major depressive disorder and serum BDNF expression: a randomly double-blind, fluoxetine-adjunct, placebo-controlled, pilot clinical study
Wu R, Zhu D, Xia Y, Wang H, Tao W, Xue W, Xia B, Ren L, Zhou X, Li GC, Chen G
Published Date: 6 August 2015
Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease
Zanini A, Cherubino F, Zampogna E, Croce S, Pignatti P, Spanevello A
Published Date: 17 June 2015
Chung JW, Kong KA, Lee JH, Lee SJ, Ryu YJ, Chang JH
Published Date: 21 July 2014
Walters EH, Walters J, Wills KE, Robinson A, Wood-Baker R
Published Date: 10 July 2012
Bastovansky A, Ziegler K, Stöllberger C, Finsterer J
Published Date: 22 June 2012
Filament formation associated with spirochetal infection: a comparative approach to Morgellons disease
Middelveen MJ, Stricker RB
Published Date: 14 November 2011
Borre M, Erichsen R, Lund L, Larsen EH, Nørgaard M, Jacobsen JB
Published Date: 21 July 2011
Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
Anand A Dalal, Meaghan St Charles, Hans V Petersen, et al
Published Date: 9 June 2010
Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care
Carl Llor, Silvia Hernández, Anna Ribas, Carmen Álvarez, Josep Maria Cots, et al
Published Date: 15 October 2008
Satu J Siiskonen, Nancy S Breekveldt-Postma, Gábor Vincze, Zeba M Khan, Joëlle A Erkens, et al
Published Date: 15 January 2008